Defendant
6 cases as defendant.
Helsinn Healthcare S.A. (commonly "Helsinn" or the Helsinn Group) is a privately held, family-owned Swiss pharmaceutical group headquartered in Lugano, Switzerland, founded in 1976 by Dr. Gabriele Braglia and now in its third/fourth generation of family ownership. It is not publicly traded and reports no ticker. Helsinn's own materials describe operating subsidiaries in the U.S. (Helsinn Therapeutics), manufacturing in Ireland (Helsinn Birex Pharmaceuticals), and offices in China; a 2020 Swiss Biotech Association profile cited "over 650 employees," though current headcount and revenue are not publicly disclosed. Note that some third-party databases contain conflicting ownership information; no reliable public source confirms those claims.
Operations. Helsinn develops, manufactures, and commercializes cancer-supportive-care and oncology products, with a stated focus on supportive care, oncology, and dermato-oncology. Its principal marketed franchises are AKYNZEO (a fixed combination of the NK1 antagonist netupitant, or its IV prodrug fosnetupitant, with the 5-HT3 antagonist palonosetron, for chemotherapy-induced nausea and vomiting) and ALOXI (palonosetron). Its model combines in-licensing, in-house development and GMP manufacturing, regulatory filings, and out-licensing to commercial partners; ALOXI's U.S. rights were licensed to Eisai (via MGI Pharma).
Litigation posture. Operating company, predominantly a defendant/target rather than an NPE. Of 5 tracked matters: 4 are defendant-side PTAB proceedings and 1 is a plaintiff-side district court suit. The four PTAB cases are inter partes reviews filed by Azurity Pharmaceuticals, Inc. on 2025-05-01 challenging Helsinn's Akynzeo-related Orange Book patents. The single plaintiff case, Helsinn Healthcare S.A. v. Gland Pharma Limited (D.N.J., filed 2022-07-18), was a Hatch-Waxman ANDA action over fosnetupitant/palonosetron injection patents; it was resolved by consent judgment and dismissal in January 2023. Venue is New Jersey, not a plaintiff-friendly NPE venue.
Context. Helsinn has historically enforced its palonosetron portfolio broadly, including the ALOXI formulation litigation against Teva, Dr. Reddy's, and Sandoz, which reached the Supreme Court in Helsinn Healthcare v. Teva (2019) on the AIA on-sale bar. That enforcement pattern is consistent with a brand pharmaceutical company protecting Orange Book-listed patents against generic challenges, not with patent assertion by a non-practicing entity.
Azurity filed an inter partes review petition challenging U.S. 10,828,297 B2, owned by Helsinn, on obviousness grounds. The Board instituted trial on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. Patent No. 9,943,515. The Board instituted review on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. 9,186,357 B2. The proceeding is pending/instituted, with preliminary response and discretionary denial briefing.
Azurity Pharmaceuticals, Inc. filed a petition for inter partes review against Helsinn Healthcare S.A. challenging U.S. Patent No. 8,623,826 B2. The Board instituted review on November 19, 2025, and the proceeding remains pending.
IPR petition filed by Dr. Reddy's Laboratories, Ltd. et al. against Helsinn challenging claims 22–27 and 30 of US 8,729,094. Institution was denied and the proceeding was terminated on 2015-10-14 following a joint motion to terminate after settlement.
Post-grant review petition by Accord Healthcare challenging claims 1-5 and 8 of US 8,598,219 under 35 USC 112 and 103. Institution was denied on 2014-11-24; Google Patents labels it '(Settlement)' but sources indicate it was not instituted.